Atea Pharmaceuticals, Inc. AVIR
We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the potential to improve the current standard of care ("SOC") for the treatment of patients with hepatitis C virus ("HCV") infection and AT-587 which we believe has the potential to be the first direct-acting antiviral ("DAA") for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus ("HEV") infection.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.4M | $48.6M | — | — | — |
| R&D | $148.0M | $144.1M | $114.2M | $81.9M | $167.2M | $38.0M | $10.2M | $6.7M | — |
| SG&A | $32.9M | $48.8M | $49.9M | $48.7M | $45.8M | $21.6M | $4.4M | $2.8M | — |
| Total operating expenses | $180.9M | $192.9M | $164.2M | $130.7M | $213.0M | $59.7M | $14.6M | $9.5M | — |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M | -$11.0M | -$14.6M | -$9.5M | — |
| Pre-tax income | -$164.5M | -$167.5M | -$134.9M | -$119.5M | $138.6M | -$10.9M | -$14.0M | — | — |
| Income tax | $6.2M | $925.0K | $1.0M | $3.6M | $17.4M | — | — | — | — |
| Net income | -$158.0M | -$168.0M | -$136.0M | -$116.0M | $121.0M | -$10.9M | -$14.0M | -$9.1M | — |
| EPS, basic | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 | -0.51 | -1.39 | — | — |
| EPS, diluted | -1.94 | -2.00 | -1.63 | -1.39 | 1.37 | -0.51 | -1.39 | -0.90 | — |
| Shares, diluted (wtd. avg.) | 81.5M | 84.3M | 83.4M | 83.2M | 88.2M | 21.6M | 10.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $95.7M | $64.7M | $143.8M | $188.7M | $764.7M | $850.1M | $21.8M | $34.6M | $15.0M |
| Short-term investments | $206.1M | $390.0M | $434.3M | $458.2M | — | — | — | — | — |
| Total current assets | $311.0M | $462.4M | $590.5M | $660.9M | $772.4M | $863.5M | $21.9M | — | — |
| Property, plant and equipment | $457.0K | $873.0K | $1.3M | $1.7M | $23.0K | $48.0K | $41.0K | — | — |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M | $863.6M | $22.1M | — | — |
| Accounts payable | $12.9M | $4.5M | $4.3M | $2.6M | $4.5M | $60.0K | $548.0K | — | — |
| Total current liabilities | $39.8M | $18.6M | $32.4M | $18.5M | $56.9M | $315.8M | $2.4M | — | — |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M | $315.8M | $2.5M | — | — |
| Retained earnings | -$522.6M | -$364.2M | -$195.8M | -$59.9M | $56.0M | -$65.2M | -$54.2M | — | — |
| Total equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M | $547.8M | -$49.6M | -$36.2M | -$27.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M | $296.7M | -$12.8M | -$7.9M | — |
| Stock-based compensation | $20.7M | $51.8M | $49.4M | $46.7M | $39.6M | $7.5M | $624.0K | $414.0K | — |
| Capital expenditure | — | — | — | $1.9M | $4.0K | $26.0K | $2.0K | $12.0K | — |
| Investing cash flow | $188.8M | $56.1M | $40.3M | -$455.4M | -$4.0K | -$26.0K | -$2.0K | -$12.0K | — |
| Financing cash flow | -$25.7M | $267.0K | $257.0K | $370.0K | $1.5M | $531.7M | — | $27.5M | — |
| Buybacks | $25.5M | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182293.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $48.6M | $351.4M | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$9.1M | -$14.0M | -$10.9M | $121.0M | -$116.0M | -$136.0M | -$168.0M | -$158.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Shareholder vote Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |